Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

Brian has Fabry disease, a lysosomal storage disorder that can cause a variety of symptoms. “It's a condition where your cells are not able to break down a certain substance, and that ...

4D-310 is under development for the treatment of Fabry disease. The drug candidate is administered through intravenous route. The drug candidate is based on vector evolution platform technology that ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Amicus Therapeutics' shares are down 15% recently despite a profitable Q3 2024 and raised FY2024 outlook. Click here to find ...

"We are committed to delivering innovative therapies and solutions for people living with Fabry disease, their families and caregivers." A biopharmaceutical company, Protalix leverages its plant ...

Mahashivratri Lottery Bumper FDA granted priority review for innovative treatment of Fabry disease, expected to be approved early next year ...